Repligen Corporation

Financials

Fluxo de caixa operacional 39.18 M15.01 M28.61 M48.1 M25.7 M 117.42 M Fluxo de caixa de investimento -64.76 M-74.11 M-7.84 M-7.78 M-208.74 M -298.47 M Fluxo de caixa de financiamento 1.45 M-5.03 M-10.13 M-239 K195 K -15.21 M Fluxo de caixa livre 32.19 M10.57 M21 M42.71 M17.39 M 91.69 M

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.

RGEN

Financials

Repligen Corporation

Notícias

Repligen inaugura terceiro centro de treinamento em instalação nos Países Baixos

Rothschild Redburn inicia cobertura de Repligen com recomendação de compra

Repligen: Advancing, Yet Much More Work Ahead (NASDAQ:RGEN)

Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?

H.C. Wainwright eleva preço-alvo das ações da Repligen com forte crescimento

Evercore prevê crescimento nos gastos de biofarmacêuticas com base em dados de pesquisa

Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Repligen na Conferência Leerink: crescimento estratégico e desafios

Repligen at Leerink Conference: Strategic Growth and Challenges

Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript

KeyBanc reitera classificação das ações da Repligen com impulso de produtos

KeyBanc reiterates Repligen stock rating on product momentum